Freeline to Participate in Upcoming Investor Conferences
31 Juillet 2023 - 1:30PM
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today
announced that the company will be participating in two upcoming
investor conferences in August. Details are as follows:
BTIG Virtual Biotechnology Conference
Freeline Chief Executive Officer Michael Parini will participate
in a fireside chat at 10 a.m. ET on Monday, August 7. Management
will also participate in one-on-one meetings as part of the virtual
conference.
Wedbush Healthcare Conference
Management will participate in one-on-one investor meetings at
the conference, which is taking place from August 8-9 at the Lotte
Palace Hotel in New York City.
A live webcast of the BTIG fireside chat will be available on
the Investors section of Freeline’s website at www.freeline.life.
An archived replay of the webcast will be available for
approximately 90 days following the presentation.
About Freeline TherapeuticsFreeline is a
clinical-stage biotechnology company focused on developing
transformative gene therapies for chronic debilitating diseases.
Freeline uses its proprietary, rationally designed AAV vector and
capsid (AAVS3), along with novel promoters and transgenes, to
deliver a functional copy of a therapeutic gene into human liver
cells, thereby expressing a persistent functional level of the
missing or dysfunctional protein into a patient’s bloodstream. The
company is currently advancing FLT201, a highly differentiated gene
therapy candidate that delivers a novel transgene, in a Phase 1/2
clinical trial in people with Gaucher disease type 1. Freeline has
additional programs in research, including one focused on
GBA1-linked Parkinson’s disease that leverages the same novel
transgene as FLT201. Freeline is headquartered in the UK and has
operations in the United States. For more information, visit
www.freeline.life or connect with Freeline on LinkedIn and
Twitter.
Media and Investor
Contact:Naomi Aokinaomi.aoki@freeline.lifeSenior Vice
President, Head of Investor Relations & Communications+ 1 617
283 4298
Freeline Therapeutics (NASDAQ:FRLN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Freeline Therapeutics (NASDAQ:FRLN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024